Last reviewed · How we verify
nintedanib-nivolumab combination therapy
nintedanib-nivolumab combination therapy is a Small molecule drug developed by AIO-Studien-gGmbH. It is currently in Phase 1 development.
At a glance
| Generic name | nintedanib-nivolumab combination therapy |
|---|---|
| Sponsor | AIO-Studien-gGmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer (PHASE1, PHASE2)
- Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nintedanib-nivolumab combination therapy CI brief — competitive landscape report
- nintedanib-nivolumab combination therapy updates RSS · CI watch RSS
- AIO-Studien-gGmbH portfolio CI
Frequently asked questions about nintedanib-nivolumab combination therapy
What is nintedanib-nivolumab combination therapy?
nintedanib-nivolumab combination therapy is a Small molecule drug developed by AIO-Studien-gGmbH.
Who makes nintedanib-nivolumab combination therapy?
nintedanib-nivolumab combination therapy is developed by AIO-Studien-gGmbH (see full AIO-Studien-gGmbH pipeline at /company/aio-studien-ggmbh).
What development phase is nintedanib-nivolumab combination therapy in?
nintedanib-nivolumab combination therapy is in Phase 1.